Jobs
-
Copley Scientific has announced the launch of the Gentle Rocker 100i device for faster sample recovery from the Next Generation Impactor (NGI). According to Copley, the Gentle Rocker 100i offers controlled agitation of the entire… Read more . . .
-
CDMO Catalent, which offers services for a full range of OINDPs, has announced the completion of the first phase of “a significant expansion” of its development and manufacturing capabilities for unit dose and bi-dose nasal… Read more . . .
-
CDMO Recipharm said that it is now offering services for reformulation of MDIs with new lower global warming potential propellants such as HFA 152a and HFO 1234ze. The company also announced that it has partnered… Read more . . .
-
According to Opiant Pharmaceuticals, a pharmacodynamic study of the company’s OPNT003 intranasal nalmefene met its primary endpoint of non-inferiority compared to intranasal naloxone, with 3 mg of OPNT003 almost twice as effective as 4 mg… Read more . . .
-
Evoke Pharma announced that the FDA has granted new drug product exclusivity for Gimoti metoclopramide nasal spray, giving the company exclusive marketing rights for 3 following the initial approval date. The FDA approved Gimoti for… Read more . . .
-
According to Neurelis, the US Patent and Trademark Office (USPTO) has issued a new patent covering Valtoco diazepam nasal spray. The abstract for US Patent No. 11,241,414, titled “Administration of benzodiazepine compositions,” says that it… Read more . . .
-
Inhaler monitoring company Adherium has announced the appointment of Francis White as VP of Global Business Development. White was most recently Managing Director of Olympus Medical in the UK and Ireland and previously held business… Read more . . .
-
According to Iliad Biotechnologies, the company has received a 3-year, $1 million grant from the National Institute of Allergy and Infectious Diseases (NIAID) at the National Institutes of Health (NIH) for pre-clinical development of its B-Tech intranasal… Read more . . .
-
Virpax Pharmaceuticals said that nasal delivery of its VRP324 dry powder cannabidiol in a rodent model produced high concentrations of CBD in the brain. In September 2021, Virpax announced that it had licensed Nanomerics’s molecular envelope… Read more . . .
-
Australian pharmaceutical company Firebrick Pharma has announced the initiation of a Phase 2 trial of its Nasodine povidone-iodine nasal spray for the reduction of viral shedding in patients with COVID-19. According to Firebrick, a 2001 pilot… Read more . . .
Featured event:
Upcoming Events
Sponsored by Intertek,, hosts of
The Inhaled & Nasal Biologics | DNA Forum
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
October 14-October 15: Advancing Bioequivalence Frameworks for Inhalation and Nasal Drug Products: Optimizing In Vitro, In Vivo, and In Silico Methods, Rockville, MD, USA
October 19-October 20: MVIC Autumn Training 2026, Lund, Sweden
October 21-October 22: MVIC Symposium, Lund, Sweden
November 10-November 11: Rescon Europe 2026, Porto, Portugal
December 9-December 11: DDL 2026, Edinburgh, Scotland